^
    Back
    Association details:
    Biomarker:EGFR mutation + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor +
    Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Research Square
    Title:

    Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real- world study

    Published date:
    11/30/2022
    Excerpt:
    The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a real-life setting....Combination therapy had a higher efficacy than EGFR-TKI alone for patients with NSCLC having concomitant EGFR and TP53 mutation.
    DOI:
    https://doi.org/10.21203/rs.3.rs-2247421/v1